Suppression of mTOR pathway in solid tumors: Lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives

Future Oncology

Volumn 11, Issue 12, 2015, Pages 1809-1828

  Ortolani, Silvia ^a   Ciccarese, Chiara ^a   Cingarlini, Sara ^a   Tortora, Giampaolo ^a   Massari, Francesco ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

everolimus; mTOR inhibitors; mTOR pathway; neuroendocrine neoplasm; renal cell carcinoma; temsirolimus

Indexed keywords

1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; APITOLISIB; AZD 2014; AZD 8055; BIOLOGICAL MARKER; BUPARLISIB; DACTOLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OMIPALISIB; PILARALISIB; RAPAMYCIN; RIDAFOROLIMUS; SAPANISERTIB; TEMSIROLIMUS; VOXTALISIB; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); KIDNEY NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84931375496     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.81     Document Type: Review

References (140)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002).
2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 149(2), 274-293 (2012).
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002).
4. Alessi DR, James SR, Downes CP et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr. Biol. 7(4), 261-269 (1997).
5. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28(6), 1075-1083 (2010).
6. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4), 257-262 (2003).
7. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 144(5), 757-768 (2011).
8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005).
9. García-Martínez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416(3), 375-385 (2008).
10. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6(11), 1122-1128 (2004).
11. Myers MP, Pass I, Batty IH et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 95(23), 13513-13518 (1998).
12. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).
13. Shekar SC, Wu H, Fu Z et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem. 280(30), 27850-27855 (2005).
14. Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152), 439-444 (2007).
15. Davies MA, Stemke-Hale K, Tellez C et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99(8), 1265-1268 (2008).
16. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93(8), 3636-3641 (1996).
17. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. USA 102(23), 8204-8209 (2005).
18. Gupta S, Ramjaun AR, Haiko P et al. Binding of Ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129(5), 957-968 (2007).
19. Hsieh AC, Costa M, Zollo O et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17(3), 249-261 (2010).
20. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32(3), 355-357 (2002).
21. Pérez-Tenorio G, Alkhori L, Olsson B et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13(12), 3577-3584 (2007).
22. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177(1), 346-352 (2007).
23. Cingarlini S, Bonomi M, Corbo V, Scarpa A, Tortora G. Profiling mTOR pathway in neuroendocrine tumors. Target Oncol. 7(3), 183-188 (2012).
24. Oshiro N, Yoshino K, Hidayat S et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9(4), 359-366 (2004).
25. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 56(17), 3895-3897 (1996).
26. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58(5), 373-395 (1996).
27. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med. Chem. 10(7), 571-581 (2010).
28. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14(5), 1286-1290 (2008).
29. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22(12), 2336-2347 (2004).
30. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004).
31. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23(23), 5347-5356 (2005).
32. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(23), 5314-5322 (2005).
33. Torisel prescribing information. 2011. www.accessdata.fda.gov/
34. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
35. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
36. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005).
37. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15(4), 428-435 (2010).
38. Hutson TE, Escudier B, Esteban E et al. Randomized Phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32(8), 760-767 (2014).
39. Duran I, Kortmansky J, Singh D et al. A Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95, 1148-1154 (2006).
40. Hobday TJ, Qin R, Reidy-Lagunes D et al. Multicenter Phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J. Clin. Oncol. pii: JCO.2014.56.2082 (2014) (Epub ahead of print).
41. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43(2), 83-95 (2004).
42. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64(1), 252-261 (2004).
43. O'Donnell A, Faivre S, Burris HA et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1588-1595 (2008).
44. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
45. Afinitor prescribing information. 2012. www.accessdata.fda.gov/
46. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514-523 (2011).
47. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11), 2438-2446 (2009).
48. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
49. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
50. Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Second-line therapy for refractory renal-cell carcinoma. Crit. Rev. Oncol. Hematol. 83(1), 112-122 (2012).
51. Motzer RJ, Barrios CH, Kim TM et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32(25), 2765-2772 (2014).
52. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311-4318 (2008).
53. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28, 69-76 (2009).
54. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2), a randomised, placebo controlled, Phase 3 study. Lancet 378(9808), 2005-2012 (2011).
55. Yao JC, Hainsworth JD, Wolin EM et al. Multivariate analysis including biomarkers in the Phase III RADIANT-2 study of octreotide LAR plus everolimus or placebo among patients with advanced neuroendocrine tumors. Presented at: 2012 Gastrointestinal Cancers Symposium. San Francisco, California, USA, 19-21 January 2012.
56. Castellano D, Bajetta E, Ashok Panneerselvam A et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the Phase III RADIANT-2 study. Oncologist 18(1), 46-53 (2013).
57. Fazio N, Granberg D, Grossman A et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the Phase 3, randomized, placebo-controlled RADIANT-2 study. Chest 143(4), 955-962 (2013).
58. Yao JC, Öberg KE, Hainsworth JD et al. Everolimus plus octreotide long-acting repeatable (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome: updated overall survival results from RADIANT-2 study. Presented at: 2013 NANETS Symposium. SC, USA, 4-5 October 2013.
59. Yao JC, Pavel M, Lombard-Bohas C et al. Everolimus (EVE) for the treatment of advanced pancreatic neuroendocrine tumors (pNET), Final overall survival (OS) results of a randomized, double-blind, placebo (PBO)-controlled, multicenter Phase III trial (RADIANT-3). Presented at: ESMO 2014 Conference. Madrid, Spain, 26-30 September 2014.
60. Panzuto F, Rinzivillo M, Fazio N et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19(9), 966-974(2014).
61. Bernard V, Lombard-Bohas C, Taquet MC et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur. J. Endocrinol. 168(5), 665-674 (2013).
62. Catena L, Bajetta E, Milione M. Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Target. Oncol. 6, 65-68 (2011).
63. Bollard J, Couderc C, Blanc M et al. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinol. 97, 331-340 (2013).
64. Fonseca PJ, Uriol E, Galván JA et al. Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol. 6(2), 441-449 (2013).
65. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323-337 (2012).
66. Négrier S, Gravis G, Pérol D et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA), a randomised Phase 2 trial. Lancet Oncol. 12(7), 673-680 (2011).
67. Rini BI, Bellmunt J, Clancy J et al. Randomized Phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32(8), 752-759 (2014).
68. Ravaud A, Barrios C, Anak O et al. Randomized Phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2A (IFN) + BEV in patients (PTS) with metastatic renal cell carcinoma (MRCC), record-2. Presented at: 37th ESMO Congress. Wien, Austria
69. September-2 October 2012.
70. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27, 2278-2287 (2009).
71. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006).
72. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer 15(1), 257-266 (2008).
73. Bajetta E, Catena L, Fazio N et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer 120(16), 2457-2463 (2014).
74. Chan J, Ryan D, Fuchs C et al. Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Presented at: 2010 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22-24 January 2010.
75. Chan JA, Blaszkowsky L, Stuart K. A prospective, Phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer 119(17), 3212-3218 (2013).
76. Zhang J, Jia Z, Li Q et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109(8), 1478-1486 (2007).
77. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32(2), 133-138 (1998).
78. Silva SR, Bowen KA, Rychahou PG et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int. J. Cancer. 128(5), 1045-1056 (2011).
79. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501-513 (2011).
80. Yao JC, Phan AT, Hess K et al. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well differentiated neuroendocrine tumors. Pancreas 44(2), 190-197 (2014).
81. Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke M. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
82. Geboes KP, Laurent S, Verroken C et al. Durable disease control with sunitinib and everolimus in well-differentiated neuroendocrine tumors of the pancreas with a high ki67 index. Presented at: 2014 ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2014.
83. Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics 4(4), 336-365 (2014).
84. Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas 42(3), 411-421 (2013).
85. Hobday TJ, Holen K, Donehower R et al. A Phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET), A Phase II Consortium (P2C) stud. Presented at: 2006 ASCO Annual Meeting. Atlanta, GE, USA, 2-6 June 2006.
86. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR), conducting the cellular signaling symphony. J. Biol. Chem. 285(19), 14071-14077 (2010).
87. Harrington LS, Findlay GM, Gray A. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166(2), 213-223 (2004).
88. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167(3), 399-403 (2004).
89. Burris Ha. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/ mTOR pathway. Cancer Chemother. Pharmacol. 71(4), 829-842 (2013).
90. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30(3), 282-290 (2012).
91. Saura C, Bendell J, Jerusalem G et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin. Cancer Res. 20(7), 1935-1945 (2014).
92. Mayer IA, Abramson VG, Isakoff SJ et al. Stand up to cancer Phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 32(12), 1202-1209 (2014).
93. Ihle NT, Lemos R Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69(1), 143-150 (2009).
94. Hong DS, Bowles DW, Falchook GS et al. A multicenter Phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 18(15), 4173-4182 (2012).
95. Bowles DW, Ma WW, Senzer N et al. A multicenter Phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br. J. Cancer 109(5), 1085-1092 (2013).
96. Bowles DW, Senzer N, Hausman D et al. A multicenter Phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs 32(6), 1197-1203 (2014).
97. Levy B, Spira A, Becker D et al. A randomized, Phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J. Thorac. Oncol. 9(7), 1031-1035 (2014).
98. Sarker D, Ang JE, Baird RD et al. First-in-human Phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21(1), 77-86 (2015).
99. Shapiro GI, Rodon J, Bedell C et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 20(1), 233-245 (2014).
100. Furman RR, Byrd JC, Flinn IW et al. Interim results from a Phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
101. Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1), 21-32 (2009).
102. She QB, Chandarlapaty S, Ye Q et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8), e3065 (2008).
103. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2(11), 1093-1103 (2003).
104. Cho DC, Hutson TE, Samlowski W et al. Two Phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118(24), 6055-6062 (2012).
105. Leighl NB, Dent S, Clemons M et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res. Treat. 108(1), 87-92 (2008).
106. Bailey HH, Mahoney MR, Ettinger DS et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 107(10), 2462-2467 (2006).
107. Ghobrial IM, Roccaro A, Hong F et al. Clinical and translational studies of a Phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin. Cancer Res. 16(3), 1033-1041 (2010).
108. Hirai H, Sootome H, Nakatsuru Y et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9(7), 1956-1967 (2010).
109. Zhao YY, Tian Y, Zhang J et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des. Devel. Ther. 8, 1827-1837 (2014).
110. Molife LR, Yan L, Vitfell-Rasmussen J et al. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J. Hematol. Oncol. 7(1), 1 (2014).
111. Hudis C, Swanton C, Janjigian YY et al. A Phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 15(6), R110 (2013).
112. Brana I, Berger R, Golan T et al. A parallel-arm Phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br. J. Cancer 111(10), 1932-1944 (2014).
113. Lin J, Sampath D, Nannini MA et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 19(7), 1760-1772 (2013).
114. Heerding DA, Rhodes N, Leber JD et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c] pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med. Chem. 51(18), 5663-5679 (2008).
115. Dumble M, Crouthamel MC, Zhang SY et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE 9(6), e100880 (2014).
116. Garlich JR, De P, Dey N et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68(1), 206-215 (2008).
117. Mahadevan D, Chiorean EG, Harris WB et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/ mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 48(18), 3319-3327 (2012).
118. Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23(9), 2399-2408 (2012).
119. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7(7), 1851-1863 (2008).
120. Cho DC, Cohen MB, Panka DJ et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 16(14), 3628-3638 (2010).
121. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 10, 90 (2011).
122. Papadopoulos KP, Tabernero J, Markman B et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/ mTOR inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 20(9), 2445-2456 (2014).
123. Britten CD, Adjei AA, Millham R et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest. New Drugs 32(3), 510-517 (2014).
124. Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7(2), e38 (2009).
125. Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284(12), 8023-8032 (2009).
126. Yu K, Toral-Barza L, Shi C et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69(15), 6232-6240 (2009).
127. Tan DS, Dumez H, Olmos D et al. First-in-human Phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
128. Wang Y, Ducker G, Shokat K et al. A primary xenograft model of pancreatic neuroendocrine carcinoma recapitulates hallmark features of the disease. Presented at: 2013 NANETS Symposium. SC, USA, 4-5 October 2013.
129. Matti L, Gild ML, Landa I et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr. Relat. Cancer 20, 659-667 (2013).
130. Giubellino A, Bullova P, Nölting S et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 154(2), 646-655 (2013).
131. Valentino JD, Li J, Zaytseva YY et al. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors. Clin. Cancer Res. 20(5), 1212-1222 (2014).
132. Fazio N, Buzzoni R, Baudin E et al. Phase II study of BEZ235 in patients with advanced pancreatic neuroendocrine tumors after mTOR inhibitor therapy failure: stage I interim results. Presented at: ESMO 2014 Conference. Madrid, Spain, 26-30 September 2014.
133. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
134. Figlin RA, de Souza P, McDermott D et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 115, 3651-3660 (2009).
135. Wang X, Yue P, Kim YA et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/ rictor-independent Akt Activation. Cancer Res. 68, 7409-7418 (2008).
136. Li S, Kong Y, Si L et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer 28(14), 376 (2014).
137. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496 (2008).
138. Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 120(8), 2858-2866 (2010).
139. Treilleux I, Arnedos M, Cropet C et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann. Oncol. 26, 120-125 (2015).
140. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 30, 3402-3407 (2012).